Just reading some trial results and two things that stand out...

Just reading some trial results and two things that stand out for me are that patients that had TG4010 had a much higher survival rate than those without and from the study they identified certain patients that did much better due to their biology. Now knowing this when they target the specific group the results will be further improved and im starting to understand why the transgene people are getting excited and going ahead with the construction of the manufacturing plant with or without novartis committing to the take up of their option.

The vaccine appeared to have other benefits as well. More patients in the vaccine group responded to treatment than patients who received only chemotherapy -- 41.9% compared to 28.4%. Also, for those patients who did respond to treatment, those given injections of the TG4010 vaccine had an average overall survival of 23.3 months, nearly twice that of patients in the comparison group.
The researchers also discovered a potential biomarker that may allow doctors to better determine which patients are most likely to benefit from the vaccine, if it reaches the market.

According to the study, patients with a normal number of a specific type of natural killer cells did much better with the vaccine than patients with an increased number of the cells. Natural killer cells are a form of white blood cell that helps the body fight off cancer cells and cells infected with viruses.

These observations "point to the importance of patients' biological status as a predictor for success of therapeutic vaccination, and suggest that analysis of biological parameters should be part of the clinical developments in cancer immunotherapy," the researchers write.

This is a very important point, says Harry Raftopoulos, MD, an oncologist at the Monter Cancer Center in Lake Success, N.Y., who reviewed the study for WebMD.

http://www.webmd.com/lung-cancer/news/20111021/vaccine-may-help-slow-spread-of-lung-cancer